CytomX outlines Q1 2026 CX-2051 data update and 100-patient enrollment milestone as Phase Ib study nears

Q3 2025 Management View CEO Sean McCarthy announced the appointment of Rachael Lester as Chief Business Officer, emphasizing ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q3 2025 Earnings Call Transcript

Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to ...
Business Insider

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the ...

Will CytomX Therapeutics’ (CTMX) New Business Chief Reshape Its Growth Strategy or Reinforce Stability?

CytomX Therapeutics recently announced the appointment of Rachael Lester as Senior Vice President and Chief Business Officer, placing her in charge of strategy and business development. Ms. Lester ...

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Leadership team addition to drive strategic long-term value creation and partnering strategySOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a ...